MBVX - MabVax Therapeutics Holdings, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
2.13
+0.04 (+1.91%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close2.09
Open2.20
Bid1.94 x 100
Ask2.98 x 500
Day's Range1.94 - 2.20
52 Week Range1.29 - 9.60
Volume268,869
Avg. Volume134,479
Market Cap16.318M
Beta1.43
PE Ratio (TTM)N/A
EPS (TTM)-10.52
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.00
Trade prices are not sourced from all markets
  • PR Newswire5 days ago

    Lifshitz & Miller LLP Announces Investigation of A10 Networks, Inc., Aerohive Networks, Inc., Jacksonville Bancorp, Inc., Key Technology, Inc., MabVax Therapeutics Holdings, Inc., MetLife Inc. and Xerox Corporation

    NEW YORK , Feb. 19, 2018 /PRNewswire/ -- A10 Networks, Inc. (ATEN) Lifshitz & Miller announces investigation into possible breaches of fiduciary duties by the board in connection with the Company's revenue ...

  • MabVax Therapeutics Schedules Previously Announced 1-for-3 Reverse Stock Split to Regain Compliance with NASDAQ's $1.00 Minimum Bid Price Maintenance Requirement
    PR Newswire9 days ago

    MabVax Therapeutics Schedules Previously Announced 1-for-3 Reverse Stock Split to Regain Compliance with NASDAQ's $1.00 Minimum Bid Price Maintenance Requirement

    SAN DIEGO , Feb. 15, 2018 /PRNewswire/ --  MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX) ("MabVax" or the "Company"), a clinical-stage biotechnology company focused on the development ...

  • MabVax Therapeutics Announces Positive Interim Data from Expanded Cohort in Phase 1 Trial Evaluating MVT-5873 in Combination with First-Line Chemotherapy in Pancreatic Cancer
    PR Newswire12 days ago

    MabVax Therapeutics Announces Positive Interim Data from Expanded Cohort in Phase 1 Trial Evaluating MVT-5873 in Combination with First-Line Chemotherapy in Pancreatic Cancer

    SAN DIEGO, Feb. 12, 2018 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (MBVX), a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, announced today positive interim results from the Company's ongoing Phase 1 trial evaluating MVT-5873 in combination with standard of care chemotherapy in patients newly diagnosed with pancreatic and other CA19-9 positive malignancies. In the Phase 1 study, MabVax's MVT-5873, a fully human antibody, was given in combination with nab-paclitaxel and gemcitabine to patients newly diagnosed with CA19-9 positive pancreatic cancer. MVT-5873 at a dose of 0.125 mg/kg when added to first-line chemotherapy was generally well tolerated by all subjects.   The Company reported that all six patients had measurable tumor reductions, with four patients meeting the criteria for partial response (PR) and two patients meeting the criteria for stable disease (SD).

  • ACCESSWIRE16 days ago

    INVESTOR NOTICE: The Schall Law Firm Announces the Investigation of Securities Claims Against MabVax Therapeutic Holdings, Inc. - MBVX

    LOS ANGELES, CA / ACCESSWIRE / February 8, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MabVax Therapeutics ...

  • MabVax to Present at BIO CEO & Investor Conference
    PR Newswire17 days ago

    MabVax to Present at BIO CEO & Investor Conference

    SAN DIEGO, Feb. 7, 2018 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (MBVX) ("MabVax" or the "Company"), a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, today announced that David Hansen, MabVax's President and Chief Executive Officer will present at the BIO CEO & Investor Conference on Monday, February 12, 2018 at 11:15 a.m. EST in New York, NY. As part of his presentation, Mr. Hansen will provide a corporate overview, including a clinical update on the Company's two lead clinical development programs: (1) Its fully human antibody therapeutic product, MVT-5873, currently in a Phase 1 clinical study in combination with gemcitabine and nab-paclitaxel in first line therapy for the treatment of newly diagnosed pancreatic cancer patients.

  • MabVax Therapeutics Closes $2.1 Million Private Placement Financing
    PR Newswire18 days ago

    MabVax Therapeutics Closes $2.1 Million Private Placement Financing

    SAN DIEGO, Feb. 6, 2018 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (the "Company") (MBVX), a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, announced today the closing of a private financing for a total of $2.1 million. The Company entered into separate purchase agreements with accredited investors pursuant to which it agreed to sell an aggregate of $2.1 million worth of shares of common stock, par value $0.01 per share at a purchase price of $0.75 per share (or, at the election of any investor who, as a result of receiving common stock would hold in excess of 4.99% of the Company's issued and outstanding common stock, shares of its newly designated 0% Series M Convertible Preferred Stock) and a three year warrant to purchase shares of common stock equal to 70% of such number of shares of common stock purchased (or, if Series M Preferred Stock, 70% of the shares of common stock issuable upon conversion of the Series M Preferred Stock).

  • ACCESSWIRE24 days ago

    IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces the Investigation of Securities Claims Against MabVax Therapeutic Holdings, Inc. - MBVX

    LOS ANGELES, CA / ACCESSWIRE / January 31, 2018 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MabVax Therapeutics ...

  • PR Newswire24 days ago

    SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of MabVax Therapeutics Holdings, Inc. (MBVX)

    NEW YORK , Jan. 31, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of MabVax Therapeutics Holdings, Inc. ("MabVax" ...

  • Business Wire24 days ago

    INVESTOR ALERT: Investigation of MabVax Therapeutics Announced by Holzer & Holzer

    Holzer & Holzer, LLC is investigating whether MabVax Therapeutics Holdings, Inc. complied with the federal securities laws. On January 30, 2018, MabVax announced that it received notice that the Securities and Exchange Commission is investigating and examining certain of the Company’s filed registration statements and subsequent amendments. The price of MabVax stock fell significantly following the ...

  • All You Need To Know About MabVax Therapeutics Holdings Inc’s (NASDAQ:MBVX) Risks
    Simply Wall St.25 days ago

    All You Need To Know About MabVax Therapeutics Holdings Inc’s (NASDAQ:MBVX) Risks

    If you are a shareholder in MabVax Therapeutics Holdings Inc’s (NASDAQ:MBVX), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile ofRead More...

  • Business Wire25 days ago

    EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against MabVax Therapeutics Holdings, Inc. – MBVX

    Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of purchasers of the securities of MabVax Therapeutics Holdings, Inc.

  • MabVax Receives Notice of SEC Investigation and Examination of Certain Registration Statements
    PR Newswire25 days ago

    MabVax Receives Notice of SEC Investigation and Examination of Certain Registration Statements

    SAN DIEGO, Jan. 30, 2018 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (MBVX) ("MabVax" or the "Company"), a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, today announced that it received notice that the Securities and Exchange Commission ("SEC") was conducting an investigation and examination pursuant to Section 8(e) of the Securities Act of 1933, as amended, relating to certain of the Company's registration statements (and amendments thereto). MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the rapid translation into clinical development of products to address unmet medical needs in the treatment of cancer.

  • How Should Investors Feel About MabVax Therapeutics Holdings Inc’s (NASDAQ:MBVX) CEO Pay?
    Simply Wall St.last month

    How Should Investors Feel About MabVax Therapeutics Holdings Inc’s (NASDAQ:MBVX) CEO Pay?

    John Hansen took the reins as CEO of MabVax Therapeutics Holdings Inc’s (NASDAQ:MBVX) and grew market cap to $18.83M recently. Understanding how CEOs are incentivised to run and grow theirRead More...

  • MabVax Therapeutics Holdings, Inc. Provides Business Strategy Update
    PR Newswirelast month

    MabVax Therapeutics Holdings, Inc. Provides Business Strategy Update

    SAN DIEGO, Jan. 16, 2018 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (MBVX), a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, today provided an update on its business strategy initiatives. In September 2017, MabVax announced its engagement with Greenhill & Co. (GHL) to serve as an advisor to assist the Company in exploring and evaluating strategic options with the goal of maximizing stockholder value. With the assistance of Greenhill, MabVax is currently in advanced discussions with a variety of interested parties for potential multiple transaction proposals as well as continuing to identify new opportunities. In parallel with the strategic initiatives efforts led by Greenhill & Co., MabVax continues to advance its Phase 1 clinical programs including the MVT-1075 radioimmunotherapy clinical trial for the treatment of pancreatic, colon and lung cancers, and the MVT-5873 clinical trial in combination with a standard of care chemotherapy as a first line therapy for patients newly diagnosed with pancreatic cancer.  In addition, the Company's lead research program, HuMab-Tn, has generated significant interest and continues as part of its discussions with external parties.

  • Is MabVax Therapeutics Holdings Inc (NASDAQ:MBVX) On The Right Side Of Disruption?
    Simply Wall St.2 months ago

    Is MabVax Therapeutics Holdings Inc (NASDAQ:MBVX) On The Right Side Of Disruption?

    MabVax Therapeutics Holdings Inc (NASDAQ:MBVX), a USD$14.82M small-cap, is a healthcare company operating in an industry, which continues to be affected by the sustained economic uncertainty and structural trends, suchRead More...

  • ACCESSWIRE2 months ago

    Wired News – MabVax Therapeutics Completes Enrollment and Initial Patient Dosing in Expanded Cohort of the Phase-1 Trial Evaluating MVT-5873

    LONDON, UK / ACCESSWIRE / December 22, 2017 / Active-Investors.com has just released a free research report on MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX ) ("MabVax"). If you want access ...

  • MabVax Therapeutics Announces Completion of Enrollment and Initial Patient Dosing in an Expanded Cohort of the Phase 1 Trial Evaluating MVT-5873 in Combination with First-Line Chemotherapy
    PR Newswire2 months ago

    MabVax Therapeutics Announces Completion of Enrollment and Initial Patient Dosing in an Expanded Cohort of the Phase 1 Trial Evaluating MVT-5873 in Combination with First-Line Chemotherapy

    In October, the Company provided an update at the AACR-NCI-EORTC International Conference highlighting encouraging preliminary tumor response data when MVT-5873 was given in combination with nab-paclitaxel and gemcitabine in newly diagnosed patients with CA19-9 positive pancreatic cancer. At this meeting the Company reported that this dose was generally well tolerated in all subjects and that two of three subjects receiving 0.125 mg/kg MVT-5873 in combination with gemcitabine plus nab-paclitaxel had a partial response ("PR"). This portion of the Company's Phase 1 clinical trial is an open-label, multi-center nonrandomized dose escalation study evaluating the safety and maximum tolerated dose ("MTD") and recommended Phase 2 dose of MVT-5873 in combination with a standard of care chemotherapy in subjects with pancreatic and other CA19-9 positive malignancies.

  • ACCESSWIRE2 months ago

    Blog Exposure - MabVax Therapeutics Completes Enrollment and Dosing In Initial Cohort of Phase-1 Trial of Its Cancer Drug MVT-1075

    Stock Monitor: BioPharmX Post Earnings Reporting LONDON, UK / ACCESSWIRE / December 15, 2017 / Active-Investors issued a free report on MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX ) ("MabVax"), ...

  • PR Newswire2 months ago

    MabVax Therapeutics Announces Completion of Enrollment and Dosing in Initial Cohort of MVT-1075 Radioimmunotherapy Phase 1 Trial for the Treatment of Pancreatic, Colon and Lung Cancers

    SAN DIEGO, Dec. 13, 2017 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (MBVX), a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, announced today the completion of enrollment and dosing of all patients in the initial cohort of the Phase 1 clinical trial evaluating the Company's new human antibody-based radioimmunotherapy ("RIT") product MVT-1075 for the treatment of pancreatic, colon and lung cancer. This Phase 1 first-in-human clinical trial is an open-label, multi-center study evaluating the safety and efficacy of MVT-1075 in approximately 22 patients with CA19-9 positive malignancies in the U.S. The primary objective is to determine the maximum tolerated dose and safety profile in patients with recurring disease who have failed prior therapies.

  • MabVax Therapeutics Holdings Inc (MBVX): Should The Recent EPS Drop Worry You?
    Simply Wall St.3 months ago

    MabVax Therapeutics Holdings Inc (MBVX): Should The Recent EPS Drop Worry You?

    In this commentary, I will examine MabVax Therapeutics Holdings Inc’s (NASDAQ:MBVX) latest earnings update (30 September 2017) and compare these figures against its performance over the past couple of years,Read More...

  • MabVax Stockholders Approve Proposals at Special Meeting of Stockholders
    PR Newswire3 months ago

    MabVax Stockholders Approve Proposals at Special Meeting of Stockholders

    SAN DIEGO , Dec. 1, 2017 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX) a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet ...

  • MabVax Announces Adjournment of Special Meeting of Stockholders
    PR Newswire3 months ago

    MabVax Announces Adjournment of Special Meeting of Stockholders

    Special Meeting to Resume on Friday, December 1, 2017 SAN DIEGO , Nov. 22, 2017 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX) a clinical-stage biotechnology company focused on the development ...

  • What Does MabVax Therapeutics Holdings Inc’s (MBVX) Share Price Indicate?
    Simply Wall St.3 months ago

    What Does MabVax Therapeutics Holdings Inc’s (MBVX) Share Price Indicate?

    MabVax Therapeutics Holdings Inc (NASDAQ:MBVX), a biotechnology company based in United States, led the NasdaqCM gainers with a relatively large price hike in the past couple of weeks. As aRead More...

  • MabVax Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Listing Requirements
    PR Newswire3 months ago

    MabVax Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Listing Requirements

    SAN DIEGO , Nov. 16, 2017 /PRNewswire/ --  MabVax Therapeutics Holdings, Inc . (NASDAQ: MBVX), a clinical-stage oncology drug development company focused on the development of antibody-based products to ...

  • MabVax Therapeutics to Present Positive Development Study Results Enabling Manufacturing of Two Radionuclide Products for Phase 1 Clinical Trials at the 2017 AAPS Annual Meeting
    PR Newswire3 months ago

    MabVax Therapeutics to Present Positive Development Study Results Enabling Manufacturing of Two Radionuclide Products for Phase 1 Clinical Trials at the 2017 AAPS Annual Meeting

    SAN DIEGO, Nov. 13, 2017 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (MBVX), a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the rapid translation into clinical development of products to address unmet medical needs in the treatment of cancer, announced today the results from the manufacturing process development and characterization of the Company's immunoPET imaging agent (MVT-2163) and radioimmunotherapy agent (MVT-1075) which are being evaluated in advanced pancreatic cancer and other CA19-9 positive cancers.  The results will be presented in a poster presentation at the American Association of Pharmaceutical Scientists to be held in San Diego, CA, November 12 - 15, 2017.